Centessa Pharmaceuticals (CNTA)
(Delayed Data from NSDQ)
$11.01 USD
+0.46 (4.36%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $11.01 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CNTA 11.01 +0.46(4.36%)
Will CNTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CNTA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CNTA
Are Medical Stocks Lagging Stryker (SYK) This Year?
Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade
CNTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
Other News for CNTA
CNTA Stock Earnings: Centessa Pharmaceuticals Misses EPS for Q2 2024
Centessa Pharmaceuticals GAAP EPS of -$0.40
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
Centessa reports Q2 EPS (40c), consensus (39c)
Centessa sees cash runway into mid-2026